Background: Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims: We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods: 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results: Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant. Conclusion: Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis

Renna S.;Cappello M.;Mendolaro M.;Inserra G.;
2018-01-01

Abstract

Background: Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims: We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods: 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results: Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in golimumab patients (p = 0.008) at the end of follow up. These data were confirmed by propensity score analysis. A further analysis considering adalimumab optimization as treatment failure showed that the difference between adalimumab and golimumab was not significant. Conclusion: Adalimumab and golimumab are effective in the treatment of ulcerative colitis. Adalimumab seems to be more effective than golimumab. This difference is probably affected by the impossibility of golimumab to be optimized in Italy while adalimumab is.
2018
Adalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies, Monoclonal; Colitis, Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha
File in questo prodotto:
File Dimensione Formato  
adalimumab and golimumab in moderate-to-severe ulcerative colitis.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Dimensione 991.11 kB
Formato Adobe PDF
991.11 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/374073
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 17
social impact